Biofrontera

Regulatory And Litigation Risks Will Constrain Growth But Enable Recovery

AnalystLowTarget

Not Invested

Community Contributor

Published

28 Aug 25

AnalystLowTarget's Fair Value

US$3.00

67.2% undervalued

04 Sep

US$0.98

-16.5%

3.5%

-16.5%

3.5%

You can edit this narrative until Aug 28 10:25 PM. Then, changes will post as Updates.

Author's Valuation

US$367.2% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$3

67.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

22.67%

Pharma revenue growth rate

0.67%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$32.82m

Earnings '28

2.61x

PE Ratio '28

US$85.60m

Market Cap '28

US$85.60m

Market Cap '28

23.44m

No. shares '28

US$3.65

Share Price '28

US$3.65 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$3.00

Fair Value '25